Biosimilar: India

A biosimilar product is a biologic medicine approved based on showing that it is highly similar to an FDA‐approved biologic drug/product, known as a reference medicine, and has no clinically meaningful differences in safety and effectiveness from the reference product/drug. Only minor differences in clinically inactive components are allowed in biosimilar products. Biosimilars are approved as per the same standards of pharmaceutical quality, safety and efficacy that apply to all biological drugs (medicine).

According to research, ‘The Indian biosimilar market size reached a value of almost USD 633 million in 2020. The market of pharmaceuticals is expected to grow at a CAGR of 11% between 2021 and 2026.’

The market expansion visibly shows the potential and need for biosimilar medicine among people. Biosimilars are also known as subsequent entry biologics (SEBs) or follow-on biologics. These are the FDA-approved biotherapeutic products that possess congruent properties with respect to their mechanism of action and efficacy as their reference biologics. They can only be manufactured after the expiration of the reference product’s patent. It requires less research and time to make; hence they are cheaper to produce, and money can be reinvested.

Ikris Pharma Networks are among the authorized international pharmaceutical wholesalers who deal with the import and export of drugs, RLD sourcing, cold chain supply, generic and innovative drug supplying and many more. To know more about our products and services, visit

About Us- Ikris Pharma Network (Pharmaceutical Wholesaler)

We are trusted partners, we follow the protocols and guidelines of good distribution practices, and are a WHO-GDP-certified company. We are approved by the Pharmaceutical export promotion council of India (Pharmexcil) and successfully completed the audit of ISO9001. Apart from that, we are registered with MSMEs. These certifications make us a more recognizable and preferred supplier in India.

Ikris Pharma Networks has expertise in sourcing branded innovator samples/ reference Listed Drugs and biosimilars which are unable to be supplied by other suppliers. We have served more than 50000+ customers among 150 countries. One can simply order the medication as per need against a valid prescription, and we make the medicine or the drug available as we deal in countries including India, USA, Europe, Canada, Australia, New Zealand, Korea, Japan, and Latin America.

For more detail about us, visit Contact us: Ikris Pharma International | Toll-Free:- 1800 889 1064

Reference-

• India Biosimilar Market Size, Share, Price, Analysis 2023-2028
• Biosimilars | FDA
• What are Biosimilars and Biologics?